Evidence map›Paper›PMID 34536116›Full record

ArticleArchives of osteoporosis2021

Biochemical characteristics and calcium and PTH levels of patients with high normal and elevated serum 25(OH)D levels in Turkey: DeVIT-TOX survey.

Zafer Pekkolay, Dilek Gogas Yavuz, Emre Sedar Saygılı, Ceyla Konca Değertekin, Ömercan Topaloğlu, Çağatay Emir Önder, Hikmet Soylu, Işılay Taskaldıran, Ayşe Esen Pazır, Kader Uğur and 15 more

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Archives of osteoporosis, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 17 institutions in 1 country.

Zafer PekkolayDepartment of Endocrinology, School of Medicine, Dicle University, Diyarbakır, Turkey. drpekkolay@gmail.com.
Dilek Gogas YavuzDepartment of Endocrinology, School of Medicine, Marmara University, İstanbul, Turkey.
Emre Sedar SaygılıDepartment of Endocrinology, Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, Turkey.
Ceyla Konca DeğertekinDeparment of Endocrinology, Ufuk University School of Medicine, Ankara, Turkey.
Ömercan TopaloğluDepartment of Endocrinology, School of Medicine, Zonguldak Bülent Ecevit University, Kocaeli, Turkey.
Çağatay Emir ÖnderDepartment of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
Hikmet SoyluGazi Yaşargil Training and Research Hospital, Endocrinology Clinic, Diyarbakır, Turkey.
Işılay TaskaldıranDepartment of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
Ayşe Esen PazırDepartment of Endocrinology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, İstanbul, Turkey.
Kader UğurDepartment of Endocrinology, Fırat University School of Medicine, Elazığ, Turkey.
Seher TanrıkuluDepartment of Endocrinology, Haydarpaşa Numune Training and Research Hospital, İstanbul, Turkey.
Sevde Nur FıratDepartment of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
Burcu Meryem AtakDepartment of Endocrinology, School of Medicine, Akdeniz University, Antalya, Turkey.
Adnan BatmanDepartment of Endocrinology, Koç University, School of Medicine, İstanbul, Turkey.
Tülay OmmaDepartment of Endocrinology, Ankara Training and Research Hospital, Ankara, Turkey.
Eylem CağıltayDepartment of Endocrinology, Sultan Abdulhamid Han Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Nilüfer ÖzdemirDepartment of Endocrinology, School of Medicine, Celal Bayar University, Manisa, Turkey.
Seher Çetinkaya AltuntaşDepartment of Endocrinology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey.
Narin Nasıroğlu İmgaDeparment of Endocrinology, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Ersen KarakılıçDepartment of Endocrinology, Çanakkale Onsekiz Mart University School of Medicine, Çanakkale, Turkey.
Zeliha HekimsoyDepartment of Endocrinology, School of Medicine, Celal Bayar University, Manisa, Turkey.
Faruk KılınçDepartment of Endocrinology, Fırat University School of Medicine, Elazığ, Turkey.
Adnan YayDepartment of Endocrinology, Sultan Abdulhamid Han Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Mustafa EroğluDepartment of Endocrinology, School of Medicine, Balıkesir University, Balıkesir, Turkey.
Alpaslan Kemal TuzcuDepartment of Endocrinology, School of Medicine, Dicle University, Diyarbakır, Turkey.
Ministry of Health · TRÇanakkale Onsekiz Mart Üniversitesi · TRDicle University · TRFırat University · TRManisa Celal Bayar University · TRSağlık Bilimleri Üniversitesi · TRAkdeniz University · TRAnkara Numune Eğitim ve Araştırma Hastanesi · TRBakırköy Dr.Sadi Konuk Eğitim ve Araştırma Hastanesi · TRBalıkesir University · TRBülent Ecevit University · TRDiyarbakır Gazi Yaşargil Eğitim ve Araştırma Hastanesi · TRHaydarpaşa Numune Eğitim ve Araştırma Hastanesi · TRKoç University · TRMarmara University · TRRecep Tayyip Erdoğan University · TRUfuk University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Vitamin D intake over the recommended dose is usually associated with high serum 25(OH)D levels and generally not associated with symptoms of hypercalcemia. High doses of cholecalciferol need to be avoided to protect against vitamin D toxicity and related complications. Strict adherence to the clinical guidelines for treating vitamin D deficiency can ensure safe and effective treatment. PURPOSE: We observed a tendency to use high doses of cholecalciferol for vitamin D deficiency treatment or vitamin D supplementation. We aimed to determine the biochemical characteristics of patients with high normal and elevated serum 25(OH)D levels.

methodsAn online invitation was sent to all tertiary endocrinology clinics in Turkey to complete an online retrospective survey (DeVIT-TOX Survey) for patients diagnosed with high serum 25(OH)D levels (> 88 ng/mL) between January 2019 and December 2019. The patients were evaluated according to the presence of signs and symptoms of hypercalcemia and doses of vitamin D intake, evaluated into the following three groups according to their 25(OH)D levels: group 1, > 150 ng/mL; group 2, 149-100 ng/mL; and group 3, 99-88 ng/mL.

resultsA total of 253 patients were included in the final analysis (female/male: 215/38; mean age, 51.5 ± 15.6 years). The average serum 25(OH)D level was 119.9 ± 33 (range, 88-455) ng/mL, and the average serum calcium level was 9.8 ± 0.7 (range, 8.1-13.1) mg/dL. Most (n = 201; 75.4%) patients were asymptomatic despite having high serum 25(OH)D and calcium levels. The serum 25(OH)D level was significantly higher in the symptomatic groups than in the asymptomatic groups (138.6 ± 64 ng/mL vs. 117.7 ± 31 ng/mL, p < 0.05). The most common cause (73.5%) associated with high serum 25(OH)D levels was the inappropriate prescription of a high dose of oral vitamin D (600.000-1.500.000 IU) for treating vitamin D deficiency/insufficiency in a short time (1-3 months). The cut-off value of 25 (OH) D level in patients with hypercalcemia was found to be 89 ng/mL [median 116.5 (89-216)].

conclusionsHigh dose of vitamin D intake is associated with a high serum 25 OH D level, without symptoms of hypercalcemia. Inappropriate prescription of vitamin D is the primary cause for elevated 25(OH) D levels and related hypercalcemia. Hypercalcemia may not be observed in every patient at very high 25(OH) D levels. Adherence to the recommendation of guidelines is essential to ensure safe and effective treatment of vitamin D deficiency.

Indexed as

CalciumVitamin DAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesTurkey25-hydroxyvitamin DCalciumVitamin D25-OH vitamin DCholecalciferolHypercalcemiaVitamin D toxicity

Identifiers

PMID34536116
OpenAlexW3199975877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.